Another delay in the review of Sarepta Therapeutics Inc.'s proposed Duchenne muscular dystrophy treatment eteplirsen seems to have stoked more optimism that FDA eventually will decide to approve the product.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?